BYPASSING THE BLOOD BRAIN BARRIER: MONOCYTES AND MACROPHAGES

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 使用常规治疗方案未能清除浸润性胶质瘤细胞会导致肿瘤复发，并导致多形性胶质母细胞瘤(GBM)患者预后不良。这是因为这些迁移细胞受到血脑屏障(BBB)和血脑肿瘤屏障(BBTB)的保护，这阻止了大多数抗癌药物的输送。我们评价了大鼠单核/巨噬细胞(Mo/mA)跨越血脑屏障的能力。这将使纳米粒子等抗癌药物能够有效地靶向浸润性肿瘤细胞，并有可能提高恶性胶质瘤的治疗效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Failure to eradicate infiltrating glioma cells using conventional treatment regimens results in tumor recurrence and is responsible for the dismal prognosis of patients with glioblastoma multiforme (GBM). This is due to the fact that these migratory cells are protected by the blood-brain barrier (BBB) and the blood brain tumor barrier (BBTB) which prevents the delivery of most anti-cancer agents. We have evaluated the ability of monocytes/macrophages (Mo/Ma) to cross the BBB in rats. This will permit access of anti-cancer agents such as nanoparticles to effectively target the infiltrating tumor cells, and potentially improve the treatment effectiveness for malignant gliomas.